Privately owned and located in Indianapolis, Indiana, Strand Diagnostics, LLC. formed in 2012 when Strand Analytical Laboratories (Established 2005) and Diagnostic ID (Established 2008) merged into one entity. Since 2009, Strand has maintained the State of New York and CLIA accreditations and has processed prostate and breast biopsy biopsy samples from almost 400,000 patients. Across the U.S. thousands of physicians routinely evaluate cancer diagnoses using the know error® system which Strand developed and markets. The patented system uses bar coding, forensic principles and DNA fingerprinting to confirm that surgical biopsy samples being evaluated belong exclusively to the patient being diagnosed and are free from contamination. Available for a diverse range of tissue types, the know error® system brings diagnostic accuracy, patient and practice safety, confirmation and confidence to the diagnostic testing cycle.
Strand also offers UroSeq® Hereditary DNA Repair Gene Panel testing includes BRCA1, BRCA2, ATM, CHEK2, HOXB13, PALB2 and RAD51D and the Lynch Syndrome genes MLH1, MSH2, MSH6, PMS2, and EPCAM. In accordance with cancer guidelines, Strand’s gene panel tests are performed on the patient’s germline DNA already collected with the know error® system. Ordering is convenient and easy—no additional specimen collection required and no need to order a special kit.